Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | March 05, 2021 | March 09, 2021 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 15, 2021 | January 20, 2021 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 11, 2026 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director · Executive Chairman | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 05, 2021 · Filed March 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,840 |
Ending reported balance
After 2021-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-05 · Exercise / conversion · Acquired 5,000 · Balance 47,840 Row 2 · 2021-03-05 · Sale · Disposed 5,000 · Balance 42,840 |
| Stock Option (Right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2021-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-05 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: Reflects the number of options outstanding after the transactions from this specific stock option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of options outstanding after the transactions from this specific stock option grant.
Mirati Therapeutics, Inc.
Report date January 15, 2021 · Filed January 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,731 |
Reported balance
After 2021-01-15 transaction · row 1
1 source rowRow 1 · 2021-01-15 · Grant · Acquired 1,475 · Balance 5,731 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.47 · Expires 2031-01-14 | Direct | 2,155 |
Reported balance
After 2021-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-15 · Grant · Acquired 2,155 · Balance 2,155 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 22,350 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 39,361 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Davy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 48,031 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 8,548 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2026-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 23,092 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.12 · Expires 2027-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 31,153 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2023 Filed Sep 14, 2023 23:33 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 392 | $2.94 | $1,150.91 |
DisclosureSEC source: 0001209191-23-049511 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 16:35 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 4,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043693 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,016 Underlying: Ordinary shares · 4,016 shares Expires 2024-07-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 21:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043558 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 26, 2023, the Reporting Person transferred 50,000 shares of Issuer common stock to The Grey Family Trust dated November 12, 1999 ("The Grey Family Trust"). The Reporting Person is trustee of The Grey Family Trust of which members of the Reporting Person's immediate family are the beneficiaries. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001209191-23-037122 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:20 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 14,608 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-23-035831 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,784 Underlying: Common Stock · 14,608 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:20 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 14,608 | $29.00 | $423,632.00 |
DisclosureSEC source: 0001209191-23-035831 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:20 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 14,608 | $2.94 | $42,889.09 |
DisclosureSEC source: 0001209191-23-035831 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:16 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-23-035565 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:36 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032653 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:58 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 14,608 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-23-027549 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 360,392 Underlying: Common Stock · 14,608 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:58 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 14,608 | $28.00 | $409,024.00 |
DisclosureSEC source: 0001209191-23-027549 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022. Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:58 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 14,608 | $2.94 | $42,889.09 |
DisclosureSEC source: 0001209191-23-027549 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed May 2, 2023 19:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 3,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026748 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,913 shares Expires 2023-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 28, 2023 Filed May 2, 2023 19:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 3,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026748 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: 15,448 Ordinary Shares previously reported as held indirectly by the Davy Trust are held directly. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 21:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-22-048532 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,406 Underlying: Common Stock · 50,000 shares Expires 2028-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 21:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionCommon Stock | 50,000 | $1.97 | $98,500.00 |
DisclosureSEC source: 0001209191-22-048532 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 22:08 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $23.51 | $0.00 |
DisclosureSEC source: 0001209191-22-034651 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:01 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-034180 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-22-032500 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 4,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026465 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 4,223 shares Expires 2022-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,139 | $98.56 | $112,259.84 |
DisclosureSEC source: 0001209191-22-026465 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 65,374 Read SEC document |
| April 29, 2022 Filed May 2, 2022 18:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 4,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026465 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 66,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 28, 2022 Filed May 2, 2022 18:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 3,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026465 · doc4.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,913 Underlying: Ordinary shares · 3,913 shares Expires 2023-04-28 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 02:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-21-070720 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-15 F1 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001209191-21-047977 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires 2023-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 4,000 | $100.05 | $400,200.00 |
DisclosureSEC source: 0001209191-21-047977 · doc4.xml · nonDerivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,000 | $100.00 | $100,000.00 |
DisclosureSEC source: 0001209191-21-047977 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 5,000 | $2.37 | $11,850.00 |
DisclosureSEC source: 0001209191-21-047977 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:42 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $16.88 | $0.00 |
DisclosureSEC source: 0001209191-21-038941 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:07 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001209191-21-035146 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2021-05-19 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 18:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 11,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029361 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 11,098 shares Expires 2021-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 18:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,993 | $94.62 | $283,197.66 |
DisclosureSEC source: 0001209191-21-029361 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 70,395 Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 18:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 11,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029361 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 73,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 18:58 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 4,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029361 · doc4.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223 Underlying: Ordinary shares · 4,223 shares Expires 2022-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionSeries A Preferred Stock · Derivative | 90,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026817 · doc4.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 20,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: By The Grey Family Trust dated November 12, 1999. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionCommon Stock | 20,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026817 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 444,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: By The Grey Family Trust dated November 12, 1999. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 18:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001209191-21-026473 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 15,000 shares Expires 2023-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 18:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 15,000 | $90.28 | $1,354,200.00 |
DisclosureSEC source: 0001209191-21-026473 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 18:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 15,000 | $2.37 | $35,550.00 |
DisclosureSEC source: 0001209191-21-026473 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 19:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026337 · doc4.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-07 F1 · derivative.exercise_date: The shares subject to the option vest on April 8, 2022. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 5,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-21-005934 · doc1.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $76.28 | $381,400.00 |
DisclosureSEC source: 0001567619-21-005934 · doc1.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,840 Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $26.49 | $132,450.00 |
DisclosureSEC source: 0001567619-21-005934 · doc1.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:16 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 2,155 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000678 · marketforms-50979.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:16 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000678 · marketforms-50979.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,731 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 10,900 | $0.00 Strike: $16.84 | $0.00 |
DisclosureSEC source: 0001214659-20-010485 · marketforms-50636.xml · derivative · entry 11 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,900 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 89 | $249.42 | $22,198.38 |
DisclosureSEC source: 0001214659-20-010485 · marketforms-50636.xml · nonDerivative · entry 10 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,019 | $248.55 | $253,268.78 |
DisclosureSEC source: 0001214659-20-010485 · marketforms-50636.xml · nonDerivative · entry 9 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $248.30 to $249.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,997 | $247.62 | $494,501.93 |
DisclosureSEC source: 0001214659-20-010485 · marketforms-50636.xml · nonDerivative · entry 8 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,364 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $247.30 to $248.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,807 | $246.73 | $445,833.52 |
DisclosureSEC source: 0001214659-20-010485 · marketforms-50636.xml · nonDerivative · entry 7 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,361 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $246.29 to $247.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.